Search Within

Christopher G Azzoli

  1. "Vincent Miller"
Formats
  1. Journal Article (29)
  2. Meeting Abstract (17)
Groups
  1. Department of Medicine (46)
  2. Solid Tumor Oncology Division (46)
  3. Thoracic Oncology (45)
  4. Survivorship Research (17)
  5. Nursing (16)
  6. Radiology, Department of (15)

More Groups

People
  1. Vincent Miller (46)
  2. Mark Kris (45)
  3. Lee Krug (28)
  4. Naiyer Rizvi (28)
  5. Gregory Riely (19)
  6. Jorge Gomez (13)

More People

Years
  1. 2013 (1)
  2. 2012 (3)
  3. 2011 (8)
  4. 2010 (4)
  5. 2009 (6)
  6. 2008 (1)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Journal of Thoracic Oncology (11)
  3. Clinical Cancer Research (7)
  4. Cancer (4)
  5. Cancer Chemotherapy and Pharmacology (4)
  6. Seminars in Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. Elsevier Inc. (13)
  3. American Association for Cancer Research (8)
  4. Springer (4)
  5. Wiley Blackwell (4)
  6. American College of Chest Physicians (1)

More Publishers

Results (46)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Journal Article

    Yu, H. A.; Sima, C. S.; Huang, J.; Solomon, S. B.; Rimner, A.; Paik, P.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    Journal Article

    Pietanza, M. C.; Gadgeel, S. M.; Dowlati, A.; Lynch, T. J.; Salgia, R.; Rowland, K. M. Jr; Wertheim, M. S.; Price, K. A.; Riely, G. J.; Azzoli, C. G.; more...
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Screening for germline EGFR T790M mutations through lung cancer genotyping
    Journal Article

    Oxnard, G. R.; Miller, V. A.; Robson, M. E.; Azzoli, C. G.; Pao, W.; Ladanyi, M.; Arcila, M. E.
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Meeting Abstract

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; Miller, V. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase 2 study of weekly albumin-bound paclitaxel (Abraxane ®) given as a two-hour infusion
    Journal Article

    Paik, P. K.; James, L. P.; Riely, G. J.; Azzoli, C. G.; Miller, V. A.; Ng, K. K.; Sima, C. S.; Heelan, R. T.; Kris, M. G.; Moore, E.; more...
    Cancer Chemotherapy and Pharmacology (2011)

    Fulltext@MSK | Save
  • Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: Safety and efficacy in a phase 1 trial
    Journal Article

    Azzoli, C. G.; Patel, J. D.; Krug, L. M.; Miller, V.; James, L.; Kris, M. G.; Ginsberg, M.; Subzwari, S.; Tyson, L.; Dunne, M.; more...
    Journal of Thoracic Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations
    Journal Article

    Riely, G. J.; Johnson, M. L.; Medina, C.; Rizvi, N. A.; Miller, V. A.; Kris, M. G.; Pietanza, M. C.; Azzoli, C. G.; Krug, L. M.; Pao, W.; more...
    Journal of Thoracic Oncology (2011)

    Fulltext@MSK | Save
  • Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Journal Article

    Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save